Prescription Prevalence and Continuing Medication Use for Secondary Prevention After Myocardial Infarction

Abstract

Treatment persistence with recommended medication after AMI is still in need of improvement. Patient education should start as soon as possible after infarction, because the greatest drops in medication use appear to occur within one year after AMI.

Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data

“…Common methods for approximation of prescription durations include approaches based on package sizes (i.e., one tablet a day, OTAD; (1)) or the defined daily dose (DDD; (2)) defined as the assumed average maintenance dose per day for a drug used for its main indication in adults . The estimation of drug coverage (COV; (3)) based on an averaged fraction of prescribed dose units obtained from the longitudinal prescription history (or a standard dose in case of a single prescription) is another common method that appears especially suitable for a sample of older people considering the large inter‐individual variability in drug clearance and the corresponding often required dose adjustments.…”

Effect of Wenxin Granule on Ventricular Remodeling and Myocardial Apoptosis in Rats with Myocardial Infarction

“…Whilst a large number of patients with MI survive into the recovery phase, patients are still confronted with the risks of recurrent acute cardiovascular events, readmission to hospital, and unfavorable quality of life [7, 8]. In addition, patients also need to manage difficulties such as severe left ventricular dysfunction and potentially the development of heart failure [9]. …”

A time course study of high on treatment platelet reactivity in acute coronary syndrome male patients on dual antiplatelet therapy

“…Recent studies have shown a discrepancy between the recommended therapy and that which is actually received despite of the strong evidence supporting the use of aspirin, clopidogrel, beta-blockers, statins, and ACE inhibitors as secondary preventive medicine following acute myocardial infarction (AMI) [22]. In a study, analyzing 30,028 AMI patients, during outpatient care, 82% of these patients received a beta-blocker, 73% a statin, 69% an ACE inhibitor, 66% aspirin, and 61% clopidogrel after 5 years with the largest decline observed in the first year following the infarction [23].…”